

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

HT-144

RRID:CVCL_0318

Type: Cell Line

Proper Citation

RRID:CVCL_0318

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0318

Proper Citation: RRID:CVCL_0318

Description: Cell line HT-144 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Melanoma

Defining Citation: [PMID:327080](#), [PMID:833871](#), [PMID:3518877](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:7459858](#), [PMID:9354451](#), [PMID:10338330](#), [PMID:10752474](#), [PMID:12068308](#), [PMID:14692828](#), [PMID:14871852](#), [PMID:15048078](#), [PMID:15467732](#), [PMID:17363583](#), [PMID:17516929](#), [PMID:20164919](#), [PMID:21654344](#), [PMID:22383533](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:26405815](#), [PMID:26589293](#), [PMID:26673621](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HT-144

Synonyms: HT 144, HT144, HT144-mel, HT144mel

Cross References: BTO:BTO_0001406, CLO:CLO_0004280, EFO:EFO_0006443, MCCL:MCC:0000211, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-63, BioGRID_ORCS_Cell_line:646, BioSample:SAMN03472749, BioSample:SAMN10988126,

cancer cell lines: CVCL_0318, CancerTools:161928, Cell_Model_Passport:SIDM00695, CGH-DB:9314-4, ChEMBL-Cells:ChEMBL3308870, ChEMBL-Targets:ChEMBL2366291, Cosmic:687436, Cosmic:889003, Cosmic:905227, Cosmic:907067, Cosmic:928717, Cosmic:929192, Cosmic:932999, Cosmic:1022276, Cosmic:1028800, Cosmic:1102379, Cosmic:1155271, Cosmic:1477411, Cosmic:2159445, Cosmic:2651883, Cosmic-CLP:907067, DepMap:ACH-000322, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:907067, GEO:GSM162902, GEO:GSM219028, GEO:GSM887140, GEO:GSM888211, GEO:GSM1669912, GEO:GSM1671957, GEO:GSM1671964, GEO:GSM1671976, GEO:GSM1671980, GEO:GSM1671984, GEO:GSM1671985, GEO:GSM1671988, GEO:GSM1671993, GEO:GSM1672009, GEO:GSM1672016, GEO:GSM1672018, GEO:GSM1672020, GEO:GSM1672021, GEO:GSM1672026, GEO:GSM1672029, GEO:GSM1672045, GEO:GSM1672059, GEO:GSM1672063, GEO:GSM3039508, IARC_TP53:21381, LiGeA:CCL_917, LINCS_LDP:LCL-1273, PharmacDB:HT144_629_2019, PRIDE:PXD002192, PRIDE:PXD030304, Progenetix:CVCL_0318, PubChem_Cell_line:CVCL_0318, Wikidata:Q54896505

ID: CVCL_0318

Record Creation Time: 20220427T220617+0000

Record Last Update: 20260829T234242+0000

Ratings and Alerts

No rating or validation information has been found for HT-144.

No alerts have been found for HT-144.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Costantini F, et al. (2026) Extracellular vesicles released from melanoma cells constitutively expressing MHC class II promote immune evasion and cancer progression. The FEBS journal, 293(11), 3320.

Wang Y, et al. (2025) Direct transdifferentiation of tumorigenic melanoma cells induces tumor cell reversion. Cell death & disease, 16(1), 563.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. Molecular systems biology, 21(8), 983.

Gadal S, et al. (2025) Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration. Cancer

research, 85(9), 1611.

Saamarthy K, et al. (2025) An optimised Bcl-3 inhibitor for melanoma treatment. British journal of pharmacology, 182(11), 2426.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Xi H, et al. (2023) Repurposing fluphenazine to suppress melanoma brain, lung and bone metastasis by inducing G0/G1 cell cycle arrest and apoptosis and disrupting autophagic flux. Clinical & experimental metastasis, 40(2), 161.

Greenstein AE, et al. (2021) Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. Oncotarget, 12(13), 1243.

Sun Q, et al. (2021) FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor. International journal of cancer, 149(3), 657.

Costantini F, et al. (2020) The Hydroxytyrosol Induces the Death for Apoptosis of Human Melanoma Cells. International journal of molecular sciences, 21(21).

Phung B, et al. (2019) The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. Cell reports, 27(12), 3573.